Table 1. Baseline for the 144 patients’ characteristics in consolidation chemotherapy (CCT) and neoadjuvant chemoradiotherapy (nCRT).
| nCRT (n = 61) | CCT (n = 83) | P value | |
|---|---|---|---|
| Age (years) | |||
| Median (range) | 56 (24–78) | 54 (20–72) | 0.34 |
| Gender | |||
| Male | 34 55.7% | 57 68.6% | 0.11 |
| Female | 27 44.3% | 26 31.4% | |
| BMI (kg/m2) | |||
| Median (range) | 23.5 (17.3–30.4) | 24.2 (18.4–33.9) | 0.34 |
| ECOG performance status | |||
| 0 | 28 45.9% | 37 44.5% | 0.87 |
| 1 | 33 54.1% | 46 55.5% | |
| Clinical T stage | |||
| T3 | 17 27.8% | 33 39.7% | 0.21 |
| T4 | 44 72.2% | 50 60.3% | |
| Clinical N stage | |||
| N0 | 12 19.6% | 12 14.4% | 0.48 |
| N1 | 38 62.2% | 50 60.2% | |
| N2 | 11 18.2% | 21 25.4% | |
| Clinical stage | |||
| II | 12 19.7% | 12 14.5% | 0.41 |
| III | 49 80.3% | 71 85.5% | |
| CEA (ng/ml) | |||
| Median (range) | 4.3(0.93-152.2) | 6.23(0.24-247.6) | 0.32 |
| <5 ng/ml | 33 54.1% | 38 45.7% | |
| ≥5 ng/ml | 28 45.9% | 45 54.3% |
Note:
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen.